Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) Stock
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
About Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is led by CEO Xiaodong Gao, employs 1,194 people, headquartered in Shijiazhuang, CN, publicly traded since 2011.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) stock trades at $20.51 with a market capitalization of $18.85B. The stock is valued at a negative price-to-earnings (P/E) ratio of -64.21, reflecting a net loss over the last twelve months, price-to-book of 15.87, price-to-sales of 21.94. Over the past 52 weeks the stock has ranged between $18.53 and $71.71, and currently trades 71.4% below its 52-week high.
On profitability, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. generates a return on equity (ROE) of -26.68% (negative, reflecting a net loss), an operating margin of -1.16%, a net profit margin of -40.21%.
The balance sheet shows a debt-to-equity ratio of 2.44 (debt more than twice shareholders' equity), a current ratio of 0.75.
300255.SZ has an average daily trading volume of 29,993,168 shares, a beta of 0.34 (historically less volatile than the overall market), 0.92B shares outstanding.
Official website: www.hbcsbio.com
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) — frequently asked questions
What is Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) stock price today?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) is currently trading at $20.51, up 1.79% today.
What is 300255.SZ P/E ratio?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s P/E ratio is -64.21. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 300255.SZ return on equity (ROE)?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s return on equity (ROE) is -26.68%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s market cap?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has a market capitalization of $18.85B.
Does 300255.SZ pay a dividend?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 300255.SZ carry?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has a debt-to-equity ratio of 2.44. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 300255.SZ's profit margin?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. reports a net profit margin of -40.21% — the share of revenue left after every cost, including tax and interest.
What sector is 300255.SZ in?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 300255.SZ listed on?
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. trades on SHZ under the ticker 300255.SZ.
What is 300255.SZ's 52-week range?
Over the last year Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has traded between $18.53 and $71.71.
Related Healthcare Stocks
Popular Stocks
Screens 300255.SZ currently matches
On the figures above, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. passes the filters for 6 of our ready-made screens, among them Large Cap Stocks, Most Shorted Stocks, High Debt to Equity Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.